Dianthus (DNTH) Therapeutics was granted FDA orphan designation for claseprubart as a treatment of myasthenia gravis, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating
- Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
- Dianthus initiated with an Outperform at Wolfe Research
- Dianthus Highlights Strong Cash Runway and Streamlined Trials
- Dianthus initiated with an Overweight at Wells Fargo